Investigation of 68GaPSMA PET/CT as an Imaging Biomarker in Solid Tumors
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Single-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane
Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer
(mCRPC) and in advanced/metastatic solid tumors patients.
Phase:
N/A
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori